Howard Sklamberg, Life Sciences & Healthcare Regulatory partner and former FDA Deputy Commissioner, was recently a guest on NPR's podcast 1A for its episode, "For the first time, the government is acknowledging marijuana's potential medical benefits." The episode discussed the recent move by Attorney General Merrick Garland to initiate the process of reclassifying cannabis as a Schedule III drug and what this change would mean for drug policy and cannabis research.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.